Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport NMJ Targeted Technique in Upper Limb Spasticity
NCT01682148Phase 3Terminated
- Sponsor
- Ipsen
- Start
- Sep 2012
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of abobotulinumtoxinA in Upper limb spasticity, sponsored by Ipsen. Started Sep 2012; status: terminated.
02
Drugs
abobotulinumtoxinA
03
Conditions
Upper limb spasticity
Beyond the preview
Go deeper on NCT01682148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682148.